MicroRNA-34c-3p target inhibiting NOTCH1 suppresses chemosensitivity and metastasis of non-small cell lung cancer

Yang, Linzhu; Chang-cheng, Lei; Zhao, Yunping; Sun, Hongwen; Yu, Qinghe; Yang, En-Ji; Zhan, Xi

doi:10.1177/0300060520904847

Cited by 13 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notch1 translocation enhances the expression of downstream target oncogenes including cyclin D1 and homeobox protein NANOG (28,29). Notch1 has been revealed to be highly expressed as an oncogene in various cancers including non-small cell lung, breast, liver and gastric cancer (30)(31)(32)(33). The present study confirmed that miR-34c-5p impaired Notch1 expression by directly binding to the 3'-UTR of Notch1 mRNA.…”

Section: Discussionsupporting

confidence: 82%

miR‑34c‑5p targets Notch1 and suppresses the metastasis and invasion of cervical cancer

Wei¹,

Wang²,

XiuMin³

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

Micro (mi)RNAs are crucial participants in the progression of cervical cancer (CC). Growing evidence indicates that miRNA (miR)-34c-5p is a pivotal tumor suppressor in numerous types of cancer and its functions in CC require further investigating. The present study demonstrated that there was a decreased level of miR-34c-5p in CC-associated cell lines compared with healthy control samples. It also demonstrated that miR-34c-5p targeted Notch1 and suppressed CC progression. Dual-Luciferase reporter assays verified the targeted relationship of miR-34c-5p and Notch1. The expression of Notch1 in HeLa cells was markedly reduced following miR-34c-5p overexpression and the proliferation, migration and invasion of HeLa cells were reduced although apoptosis was accelerated. However, overexpression of miR-34c-5p was reversed following the addition of Notch1, which supported the finding of the targeted relationship between miR-34c-5p and Notch1. Flow cytometry demonstrated that miR-34c-5p inhibited the proliferation of HeLa cells while accelerating apoptosis. The present study concluded that miR-34c-5p was a tumor suppressor in CC and may be a novel measure for the future treatment of CC.

show abstract

Section: Discussionsupporting

confidence: 82%

miR‑34c‑5p targets Notch1 and suppresses the metastasis and invasion of cervical cancer

Wei¹,

Wang²,

XiuMin³

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…miR-21 PTEN [55][56][57][58] miR-27a RKIP [59,60] miR-92b-3p PTEN [23,61] miR-130b PTEN [62] miR-146a CHOP [54] miR-224 p-21 [62] miR-324-5p FBXO11 [63] miR-425-3p AKT1 [26] miR-1269b PTEN [64] let7 a,b,c,d,e,f,g,i LIN28 [36,48] miR-29c AKT2 [65] miR-30b-5p LRP8 [66] miR-34c-3p Notch [35] miR-100-5p mTOR [25] miR-101 ABCC1, ROCK2 [67,68] miR-145-5p ABCC1 [69] miR-146a JNK2, CEACAM6, CCNJ [70][71][72] miR-181b BCL2, TGFβR1, Notch2 [73][74][75][76] miR-193 LRRC1 [77] miR-378 sCLU [78] miR-379 EIF4G2 [79] miR-381 NFkB [80] miR-451a MCL-1 [81][82][83] miR-486-5p TWF1 [84] miR-613 GJA1 [85,86] DDP-cisplatin; DDP-S miRNA-miRNA associated with DDP sensitivity; DDP-R miRNA-miRNA associated with DDP resistance.…”

Section: Ddp R/ddp S Mirna Downstream Regulation Referencementioning

confidence: 99%

MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin

Konoshenko

Lansukhay

Красильников

et al. 2022

IJMS

View full text Add to dashboard Cite

Background: Platinum-based chemotherapy, cisplatin (DDP) specifically, is the main strategy for treating lung cancer (LC). However, currently, there is a lack of predictive drug-resistance markers, and there is increased interest in the development of a reliable and sensitive panels of markers for DDP chemotherapy-effectiveness prediction. MicroRNAs represent a perspective pool of markers for chemotherapy effectiveness. Objectives: Data on miRNAs associated with LC DDP chemotherapy response are summarized and analyzed. Materials and methods: A comprehensive review of the data in the literature and an analysis of bioinformatics resources were performed. The gene targets of miRNAs, as well as their reciprocal relationships with miRNAs, were studied using several databases. Results and Discussion: The complex analysis of bioinformatics resources and the literature indicated that the expressions of 12 miRNAs have a high predictive potential for LC DDP chemotherapy responses. The obtained information was discussed from the point of view of the main mechanisms of LC chemoresistance. Conclusions: An overview of the published data and bioinformatics resources, with respect to the predictive microRNA markers of chemotherapy response, is presented in this review. The selected microRNAs and gene panel have a high potential for predicting LC DDP sensitiveness or DDP resistance as well as for the development of a DDP co-therapy.

show abstract

“…Cai et al found that miR-128-3p upregulation increased resistance to multiple drugs though used alone (cisplatin, gemcitabine, or paclitaxel; [ 62 ]), probably suggesting a similar effect when combined therapy would be otherwise used. Other miRNAs were also identified to regulate sensitivity to both cisplatin and paclitaxel (i.e., miR-186-5p [ 63 , 64 ]; miR-17-5p [ 22 , 65 , 66 ]; miR-34c-3p [ 67 ]) or cisplatin and docetaxel (miR-141-3p [ 68 , 69 ]; and miR-379-5p [ 70 , 71 ]).…”

Section: Relevant Sectionsmentioning

confidence: 99%

MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going

Cuttano

Afanga

Bianchi

2022

Cancers

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related mortality in the world. The development of drug resistance represents a major challenge for the clinical management of patients. In the last years, microRNAs have emerged as critical modulators of anticancer therapy response. Here, we make a critical appraisal of the literature available on the role of miRNAs in the regulation of drug resistance in non-small cell lung cancer (NSCLC). We performed a comprehensive annotation of miRNAs expression profiles in chemoresistant versus sensitive NSCLC, of the drug resistance mechanisms tuned up by miRNAs, and of the relative experimental evidence in support of these. Furthermore, we described the pros and cons of experimental approaches used to investigate miRNAs in the context of therapeutic resistance, to highlight potential limitations which should be overcome to translate experimental evidence into practice ultimately improving NSCLC therapy.

show abstract

MicroRNA-34c-3p target inhibiting NOTCH1 suppresses chemosensitivity and metastasis of non-small cell lung cancer

Cited by 13 publications

References 25 publications

miR‑34c‑5p targets Notch1 and suppresses the metastasis and invasion of cervical cancer

miR‑34c‑5p targets Notch1 and suppresses the metastasis and invasion of cervical cancer

MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin

MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going

Contact Info

Product

Resources

About